Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190014/S011

MyChoice CDx

Myriad Genetic Laboratories, Inc. · Decision date Mar 10, 2026

FDA DECISIONP190014/S011

What did the FDA approve?

FDA records P190014/S011 as a supplement to PMA P190014, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Mar 10, 2026.

FDA approval order statement

Approval to update the MyChoice CDx assay labeling from a complementary diagnostic to a companion diagnostic to aid in identifying ovarian cancer patients with deleterious or suspected deleterious germline or somatic BRCA1 and BRCA2 mutations and/or a positive genomic instability score, who are eligible or may become eligible for treatment with Zejula (niraparib).
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Pathology
Decision date
Mar 10, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P190014/S011
Regulatory pathway
PMA supplement
Product code
PJG
Decision code
APPR
Decision date
Mar 10, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Cancer-related germline gene mutation detection system.

Product code
PJG
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P190014/S011 received

    Application receipt date recorded by FDA.

  2. P190014/S011 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P190014. View FDA’s full supplement list.

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Myriad Genetic Laboratories, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
320 Wankara Way, Salt Lake City, UT, 84108

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records